You are considered INTERMEDIATE-2 RISK. According to one study1 median Intermediate-2 survival for MF patients is estimated to be 33 months. Other prognostic scales2 using additional risk factors estimate much shorter survival times for higher levels of risk.
Without further treatment, nearly half of the patients at Intermediate-2 will die of their disease within 33 months. At this time you should definitely review your stem cell transplant options with your hematologist and transplant team. Some patients may decide to undergo a transplant now. Others may prefer to wait. As your decision will depend on weighing many factors, both personal and medical, this is the time to huddle with your hematologist, transplant physician, family, friends and your support team and come to a definitive decision.
Because of the great differences among patients, survival figures are only approximate. A patient’s condition, genetic predisposition, and co-morbidities are just some of the factors that play a role in longevity. It is important to review your Risk Level with your hematologist both for accuracy and for inclusion of additional factors that might impact your therapeutic options. Some of those factors are fibrosis grade, swollen spleen, transfusion dependence, high risk mutations, and defective chromosomes.
What is known for certain is that qualified patients who start stem cell transplant in good condition and early enough in the MF disease process have far better outcomes than patients who wait until the onset of end-stage symptoms.3
See Notes on MPN mutations for details on your individual mutations